MIT, South Africa announce plans to join patent pool for 'neglected diseases'

The pool was set up last year by GlaxoSmithKline (GSK) and "contains more than 2300 patents that are available for use by industry, non-profit groups and academic researchers to develop new medicines for malaria, cholera and more than a dozen other diseases," Reuters reports. The pool also includes contributions from Alnylam Pharmaceuticals and the Emory Institute for Drug Discovery and is administered by BIO Ventures in Global Health, the news service reports (Steenhuysen, 5/5).

An enormous boost

According to a GSK press release, "initially, TIA will focus on developing new medicines for tuberculosis and malaria" (5/5). TIA chair Mamphela Ramphele said, "This patent pool is an enormous boost for us to have a significant impact [on TB] in South Africa… We are extremely anxious to be able to produce new drugs to address this disease," Ramphele added, Reuters reports.

Melinda Moree, chief executive of BIO Ventures for Global Health, explained that the pool offers "expertise and know-how [which] are often some of the more valuable aspects of drug development, and also things that companies don't usually share." Moree, who noted that the pool is "a step on the part of industry to try a new model," also said that there are other large drug companies interested in contributing to the pool, according to Reuters.